Indian govt study exhorts companies to navigate and capitalize on patent cliff

30 April 2024
patent_innovation_money

As over 20 drugs with a combined annual sales value of $250 billion are set to go off-patent, Indian companies have been exhorted to step in with generic and biosimilar versions.

Noting that a massive market opportunity awaits generic drug manufacturers, the Indian government is encouraging domestic pharma majors to seize the opportunity in a global market seeking economical solutions by manufacturing affordable alternatives, reports The Pharma Letter’s India correspondent.

A study for the Department of Pharmaceuticals study has revealed that by 2030, patents for 24 major blockbuster drugs, including global top-sellers like Humira (adalimumab), Keytruda (pembrolizumab), Opdivo (nivolumab), Ibrance (palbociclib) and Symbicort (budesonide) will expire, unleashing a market valued at over $250 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biosimilars